SELLAS Phase 3 AML Win Lifts SLS 156%, Then a $150 Million Offering Follows
SELLAS said its AML vaccine met the main goal of a Phase 3 trial. Shares closed up 156.36% from Monday after a pre-market high of $34.19, then traded lower after hours once the company filed for a $150 million stock offering.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) said on Nov. 17 that its Phase 3 REGAL trial of galinpepimut-S (GPS), a vaccine for acute myeloid leukemia (AML), met its primary goal of improving overall survival, according to an 8-K filed at 7:14 a.m. ET, before the open. At 4:14 p.m. ET, in after-hours trading, it filed a preliminary prospectus supplement for a $150 million common stock offering.
A tripling pre-market, a 20% fade, then new share supply
The REGAL result sent SLS from Monday's $7.47 close to a pre-market high of $34.19. The stock fell 20.21% during the regular session from its pre-market close and still finished up 156.36% on the day. The offering filing arrived after the close, and shares traded lower in after-hours trading.
Shares more than tripled pre-market, then fell back
Nasdaq halted SLS at 6:55 a.m. ET with news pending, and trading resumed at 7:30 a.m. The stock had already gained 6.96% in Monday's after-hours session (trading after the 4 p.m. close), reaching $7.99, before the trial news.
In pre-market trading (the session before the 9:30 a.m. open), SLS was at $24.00 at 9:29 a.m., up 221.29% from Monday's close. About 25.71 million shares changed hands in that session.
Two volatility pauses hit in the regular session, from 9:35 a.m. to 9:45 a.m. and from 9:50 a.m. to 9:55 a.m. The stock ranged from $16.70 to $24.89 and closed at $19.15, up 156.36% from Monday's close. Volume was 88.23 million shares, against a 10-day average of about 6.5 million.
In after-hours trading, SLS was at $16.99 at 4:46 p.m., down 11.28% from the 4 p.m. close, on about 5.30 million shares. It is not clear whether the slide began before the 4:14 p.m. filing.
Before the news, SLS had fallen 28.79% over the sessions from Oct. 19 to Nov. 16. It closed below $8.50 in each of the last five sessions, ending at $7.47 on Monday.
What the trial data and the offering add to the picture
The company said GPS cut the risk of death by 41%, with a hazard ratio of 0.59 (a ratio below 1 means lower risk in the treated group) and a p-value of 0.035. Median overall survival was 24.0 months with GPS versus 14.7 months with the investigator's choice of best available treatment.
The offering covers up to $150 million of common stock, and underwriters have a 30-day option to buy more, according to the filing. The prospectus is preliminary and subject to completion, and it cites Monday's $7.47 close as the last reported price. The float (shares available to trade) was about 200.08 million shares.
What REGAL showed and what remains open
- The analysis was run after the pre-specified 80 deaths, the company said.
- The trial enrolled AML patients in second or later complete remission who were ineligible for, or unable to undergo, a stem cell transplant.
- The company said GPS was generally well tolerated, with mostly mild to moderate side effects such as injection site reactions, and no new safety signals.
- Secondary endpoints and other analyses are still being evaluated. The company said it will present them at a future major medical conference and submit them for peer-reviewed publication.
SELLAS also has a second AML program, SLS009. It said on Nov. 4 that it would present Phase 2 data for it at the ASH 2026 meeting.
Next steps for GPS and the offering
- Pricing of the stock offering and any exercise of the underwriters' 30-day option.
- A meeting with the FDA to discuss an accelerated filing strategy, with no date given.
- A Biologics License Application (BLA), the formal request for approval, which the company is preparing for the first half of 2027.
- Detailed secondary-endpoint results at a medical conference, with no date given.
- The ASH 2026 presentation of SLS009 data.
Bottom line
REGAL gave SELLAS a positive Phase 3 result and a stated path toward an FDA filing in the first half of 2027. The stock ended the regular session at $19.15, well above Monday's $7.47 but 20.21% below its pre-market close.
The company's $150 million offering would add shares, and the final terms are not yet in the preliminary filing. After-hours trading at $16.99 was still in progress at 4:46 p.m. ET.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




